Effect of phacoemulsification with intraocular lens implantation in eyes with cataract and functioning filtering blebs

Devendra Maheshwari, Rengappa Ramakrishanan, Mohideen Abdul Kader, Neelam Pawar, Ankit Gupta
Aravind-Zeiss Centre for Excellence in Glaucoma, Aravind Eye Hospital & Postgraduate Institute of Ophthalmology, Tirunelveli, India

Abstract

Aim: To evaluate the effect of phacoemulsification with intraocular lens implantation in eyes with pre-existing trabeculectomy.

Methods: This prospective single-center clinical study evaluated intraocular pressure in 60 eyes of 60 patients who underwent phacoemulsification and implantation of a foldable intraocular lens after a previous successful trabeculectomy. Patients who had a trabeculectomy more than one year prior to the study were included. Intraocular pressure, number of antiglaucoma medications, bleb appearance, and visual acuity were recorded preoperatively, and at each follow-up examination and 12 months after phacoemulsification.

Results: The mean intraocular pressure before phacoemulsification was 12.42 mmHg (SD, 4.60 mmHg), which increased to 14.98 mmHg (SD, 4.18 mmHg), 14.47 mmHg (SD, 3.58 mmHg), 15.44 mmHg (SD, 3.60 mmHg), and 15.71 mmHg (SD, 3.47 mmHg) after one, three, six, and 12 months, respectively. At each follow-up visit, the mean IOP was significantly higher than the preoperative value (p < 0.001, p = 0.015, p ≤ 0.001, and p = 0.001 at month one, three, six, and 12, respectively). The mean preoperative best-corrected visual acuity was 0.98 logMAR (SD, 0.44 logMAR) and the mean postoperative best-corrected visual acuity at 12 months was 0.20 logMAR (SD, 0.21 logMAR) [p = 0.0001]. The mean preoperative number of antiglaucoma medications used was 0.57 (SD, 0.63), which increased to 0.65 (SD, 0.63), 0.70 (SD, 0.72) 0.68, (SD, 0.70), and 0.67 (SD, 0.77) at one, three, six, and 12 months, respectively, but there were no statistically significant differences. Bleb size decreased clinically after phacoemulsification. Nineteen of 60 eyes (32%) developed fibrosis of bleb with decreased bleb size.

Conclusion: Phacoemulsification with intraocular lens implantation significantly increased intraocular pressure and increased the number of antiglaucoma medications in eyes with pre-existing functioning filtering blebs.

Key words: Phacoemulsification, intraocular pressure, trabeculectomy, lens implantation, intraocular

Introduction

A well-functioning bleb is a sign of successful trabeculectomy surgery. The development of a cataract is one of the calculated risks of filtering surgery.1-4 Cataract surgery in a patient with previous trabeculectomy is generally considered to have an adverse effect on the long-term survival of the filtering bleb. A few retrospective studies have
Phacoemulsification in eyes with cataract and functioning filtering blebs

evaluated the effects of phacoemulsification on filtering blebs.\textsuperscript{3,5-8} Most of these retrospective studies have shown that intraocular pressure (IOP) control is worsened or that greater numbers of antiglaucoma medications are required after phacoemulsification,\textsuperscript{6,7} while a few studies have shown no negative effect on IOP or on the number of antiglaucoma medications required.\textsuperscript{5,8,9} Park \textit{et al.} suggested that the impairment of IOP control after clear corneal incision phacoemulsification in eyes with previous trabeculectomy is comparable to that of the natural course of trabeculectomy.\textsuperscript{5} The aim of this prospective study was to evaluate the effects of temporal clear corneal phacoemulsification on IOP control and bleb appearance in eyes with a filtering bleb.

\textbf{Methods}

\textit{Patients}

This prospective study was performed between January 2007 and December 2008 at Aravind Eye Hospital, a tertiary eye care referral center in Tirunelveli, South India. Patients who had undergone a successful trabeculectomy at least one year previously and required phacoemulsification for cataract were enrolled. Patients with acute angle closure, secondary angle-closure glaucoma, inflammatory glaucoma, neovascular glaucoma, IOP > 21 mmHg with antiglaucoma medications before cataract surgery, or a follow-up duration of < 12 months were excluded. The institutional review board approved the study.

\textit{Design}

The following preoperative data were recorded for all patients: age at time of phacoemulsification, sex, glaucoma diagnosis, type of cataract, time since the most recent trabeculectomy, IOP (measured by Goldmann tonometry), and best-corrected visual acuity (BCVA). Intraoperative iris manipulation, intraocular lens (IOL) type and placement, and intraoperative and postoperative complications were also recorded. Variables retrieved from the patients’ medical records included the type of antifibrosis agent used in the trabeculectomy, and BCVA, IOP, and antiglaucoma medications prior to trabeculectomy.

Patients were examined at one week and one, three, six, and 12 months after surgery (and more often when necessary). BCVA, biomicroscopic examination, IOP, postoperative complications, and number of antiglaucoma medications were noted at each follow-up visit. Use of antiglaucoma medications was reported as the number of drugs taken, with no differentiation as to the type or frequency of medication use. Visual fields were assessed by static perimetric analysis (Humphrey Field Analyzer, 24-2; Carl Zeiss Meditec, Dublin, USA) at six months and one year after phacoemulsification.

The appearance of the filtering bleb before phacoemulsification was compared clinically with that after phacoemulsification. Changes in bleb size (area and/or height) and vessel density were recorded as unchanged, reduced, or increased at each visit. Quantitative classification of the filtering bleb was used to detect large changes in the bleb appearance before phacoemulsification and at each follow-up visit, as follows:\textsuperscript{10}
• grade 0 = no conjunctival elevation
• grade 1 = localized conjunctival elevation at the trabeculectomy site
• grade 2 = elevation of approximately 90° around the trabeculectomy site
• grade 3 = elevation of > 90° and < 180°
• grade 4 = conjunctival elevation ≥ 180°.

Surgical success of the trabeculectomy was expressed as follows:
• complete success = IOP < 17 mmHg without antiglaucoma medication
• relative success = IOP < 17 mmHg with antiglaucoma medication
• failure = IOP > 17 mmHg with antiglaucoma medication.

Procedure
All phacoemulsification procedures were performed by one of the authors. The technique and general protocol were similar for all patients. A clear corneal temporal phacoemulsification was performed under topical anesthesia, and there was no conjunctival manipulation. Posterior synechiolysis and/or pupil stretching were performed as needed. A foldable acrylic posterior chamber IOL (AcrySof SA60AT or AcrySof MA60BM; Alcon, Fort Worth, Texas, USA) was inserted into the capsular bag. When necessary, 10-0 nylon sutures were used to close the temporal wound. No sutures were passed through the bleb. Care was taken at the conclusion of surgery. Thorough removal of viscoelastic was done.

The usual postoperative treatment included a combination of dexamethasone and tobramycin five or six times daily for two weeks. The dosage was tapered by one drop weekly until discontinuation after eight weeks.

If newly-onset bleb flattening occurred, when the vessel density into or around the bleb increased or when the IOP increased, postoperative anti-inflammatory treatment was intensified by giving prednisolone acetate every one to two hours during waking hours. Two patients required needle revision of the bleb and antiglaucoma medications. The procedure was performed under an operating microscope. Topical anesthesia was applied to the eye three times, with one minute between each drop. The conjunctiva was entered several mm from the flap site with a 27-gauge needle mounted on an insulin syringe. Aqueous flow was established in one patient after perforation of the scar tissue around an encysted bleb, whereas it was necessary to dissect beneath the scleral flap and enter the anterior chamber for the other patient. 5-Fluorouracil 5 mg (25 mg/mL) was injected into the subconjunctival space around the bleb. After needling, all hypotensive therapies were stopped and replaced by an intensive topical steroid/antibiotic combination.

Statistical analysis
Longitudinal comparisons of IOP were made by using two-tailed Student’s t test for paired samples. Comparisons of BCVA and the number of glaucoma medications were tested by using Wilcoxon signed-rank test. The probability of success after phacoemulsification was estimated by using Kaplan-Meier survival analysis. The distribution of survival rates for preoperative and intraoperative factors was compared by using the log-rank test.

The Statistical Package for the Social Sciences 14.0 for Windows (SPSS Inc, Chicago,
Phacoemulsification in eyes with cataract and functioning filtering blebs

Illinois, USA) was used for all analysis. A p value of ≤ 0.05 was considered statistically significant.

**Results**

Sixty eyes of 60 patients who had undergone a previous successful trabeculectomy and for who phacoemulsification was indicated were enrolled. The demographic data of the patients are presented in Table 1. The most frequent preoperative diagnosis was primary open-angle glaucoma. An acrylic foldable posterior chamber IOL was inserted into the capsular bag in 59 eyes and into the ciliary sulcus in one eye. Iris hooks or synechiolysis were used to enlarge the pupil in nine eyes (15.0%) during phacoemulsification, one of which had a posterior capsule tear without vitreous loss and a posterior chamber IOL was implanted into the ciliary sulcus. The mean number of glaucoma medications used before phacoemulsification ranged from zero to two (Table 1).

The mean IOP before phacoemulsification and at each follow-up visit is shown in Table 2. After phacoemulsification, the mean IOP increased significantly compared with the mean IOP before phacoemulsification by 2.56 mmHg after one month (p < 0.001), 2.05 mmHg after three months (p = 0.015), 3.02 mmHg after six months (p < 0.001), and 3.29 mmHg at the last visit (p =0.001; two-tailed Student’s t test). At all follow-up visits, the IOP remained significantly higher than before phacoemulsification (p < 0.001) (Table 2).

A decrease in bleb size was observed in 38 eyes (63.3%), 42 eyes (70.0%) and 46 eyes (77.6%) at three, six, and 12 months, respectively. The bleb size did not increase during follow-up. At the last follow-up visit, 11 eyes with primary angle-closure glaucoma and eight eyes with primary open-angle glaucoma developed fibrosis.

On the first day after phacoemulsification, nine eyes (15.0%) had an IOP spike > 10 mmHg above the IOP before phacoemulsification. One eye (1.7%) had an IOP > 30 mmHg on day one postoperatively. The IOP increment was significantly greater in eyes with an IOP of ≤ 10 mmHg before phacoemulsification (5.28 mmHg [SD, 5.81 mmHg]) compared with eyes with a preoperative IOP > 10 mmHg (2.25 mmHg [SD, 4.34 mmHg]) [P = 0.012; Student’s t test]. One month after phacoemulsification, the mean number of antiglaucoma medications increased from 0.57 (SD, 0.62) to 0.67 (SD, 0.77) [p = 0.65, Wilcoxon signed-rank test] and remained increased at all postoperative visits (Table 3). Eyes with IOPs ≤ 10 mmHg before phacoemulsification had a 94.1% probability of not needing medications after phacoemulsification versus 52.8% for eyes with IOPs > 10 mmHg before phacoemulsification. At the last follow-up visit, the mean number of antiglaucoma medications was 0.67 (SD, 0.77; range, 0-3; p = 0.51). At the last visit, antiglaucoma medication was required in 17 eyes (28.33%), eight of which needed antiglaucoma medication at the one-month postoperative visit.

The success rates after phacoemulsification were 83.6%, 73.3%, and 71.6% at one month, six months and one year, respectively (Kaplan-Meier survival analysis). In two eyes, IOP was not controlled with antiglaucoma medication and required needling, one of which required repeat trabeculectomy.

Bleb size clinically decreased after phacoemulsification; 31.7% of eyes developed bleb fibrosis with a decrease in bleb size in 36.7% of eyes in the primary angle-closure glaucoma group and 26.7% of eyes in the primary open-angle glaucoma group.
developed fibrosis of the previously elevated bleb. There was no statistically significant
difference between eyes with primary open-angle glaucoma and primary angle-closure
glaucoma ($p = 0.793$).

The BCVA improved significantly after phacoemulsification, from a mean of 0.20
(0.69 logMAR) before surgery to 0.98 (0.26 logMAR) after one year ($p = 0.001$; Wilcoxon
signed-rank test). Fifty-two eyes (86.7%) had improved BCVA at the last visit compared
with the preoperative BCVA. BCVA did not improve in eight eyes. Forty-three eyes (71.7
%) achieved a final BCVA of 0.5 or better. Comparison of BCVA before trabeculectomy
(0.98; 0.30 logMAR) with that at the last visit after phacoemulsification showed that five
eyes (8.3%) had the same BCVA, 52 eyes (86.7%) had better BCVA, and three eyes (5%)
had worse BCVA.

Discussion

There are several studies on IOP change after phacoemulsification in eyes that have
undergone glaucoma filtering surgery.3,6,7,10-13 However, comparison among these
studies is difficult because of their different protocols. A specific glaucoma diagnosis is
important when considering the effect of phacoemulsification after trabeculectomy to
exclude variables that could affect IOP control such as acute angle-closure glaucoma or
secondary glaucoma. Only a few studies included a large number of patients.3,6,10 Allen et
al.13 and Rebolleda and Muñoz-Negrete7 reported that phacoemulsification significantly
increased IOP and the number of antiglaucoma medications in eyes with pre-existing
functioning filtering blebs. The functioning of the pre-existing filtering bleb may be
compromised by phacoemulsification, thus causing an IOP increase, even when a clear
corneal incision is performed and surgical precautions are taken to preserve the area of
the bleb.3-5,8,9 There are various reports in the literature regarding long-term increase in
IOP after phacoemulsification in eyes with filtering blebs (Table 4).5-7,8,14,15

Park et al.5 reported that IOP was not significantly different one year after phacoemul-
sification from the value before phacoemulsification, although three eyes requiring
additional glaucoma surgery were excluded from the analysis. In this study, IOP before
phacoemulsification also had a significant effect on the possibility of failure ($p = 0.0023$).
Patients who maintained IOP control without additional medication after cataract
surgery had a significantly lower mean IOP before phacoemulsification than those
whose surgery was classified as failure ($p = 0.008$), and the success rate was significantly
higher for patients who had an IOP ≤ 10 mmHg before phacoemulsification.

A statistically significant increase in the mean number of glaucoma medications used
after phacoemulsification was observed, although this was significantly lower than the
number used before trabeculectomy at all intervals after phacoemulsification. Eyes with
IOP ≤ 10 mmHg before phacoemulsification had a 94.1% probability of not needing
medications after phacoemulsification compared with 52.8% for eyes with IOP > 10
mmHg before phacoemulsification. In this study, a decrease in bleb size was observed in
77.6% of eyes. Similarly, bleb scarring occurred in most eyes after phacoemulsification,
but diminished during the follow-up period. Fibrosis of the bleb with a decrease in bleb
size developed in 31.7% of eyes (36.7% of eyes in the primary angle-closure glaucoma
group and 26.7% of eyes in the primary open-angle glaucoma group). There was no
statistically significant difference between eyes with primary open-angle glaucoma and those with primary angle-closure glaucoma ($p = 0.793$).

Wygnanski-Jaffe et al. have also observed bleb scarring and shrinkage after cataract extraction, sometimes with worsened IOP control. The mechanism that induces IOP elevation and flattening of the filtering bleb after cataract surgery is not known. It is likely that the inflammatory response elicited by surgery induces subconjunctival scarring, flattening of the filtering bleb, and the subsequent IOP increase that occurs postoperatively.

In this study, BCVA improved in most eyes ($n = 52; 86.7\%$) after phacoemulsification, whereas BCVA worsened in three eyes ($5.0\%$). Watson et al. followed 150 eyes of 94 patients for up to 22 years and concluded that, despite successful trabeculectomy, $59\%$ of patients had progression of visual field damage. These authors further concluded that there was a ‘long-term reduction in the visual acuity and visual fields of about one-third of the patients’, unrelated to postoperative IOP, preoperative visual field, or other definable factors. Cataract extraction justifies the improvement in visual fields observed postoperatively. There is always a possibility of decreased IOP control over time after successful trabeculectomy, even without non-glaucoma related surgical interventions.

In this study, a statistically significant increase in IOP and number of glaucoma medications was observed at each postoperative visit after phacoemulsification, despite all eyes having a well-functioning bleb. In conclusion, performing phacoemulsification after successful trabeculectomy may trigger bleb failure in eyes with a pre-existing filtering bleb and a permanent increase in IOP could be precipitated.

References

Table 1
Demographic and clinical characteristics of 60 patients who underwent phacoemulsification and implantation of a foldable intraocular lens after a previous successful trabeculectomy.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>33 (55.0)</td>
</tr>
<tr>
<td>Female</td>
<td>27 (45.0)</td>
</tr>
<tr>
<td><strong>Eye</strong></td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>28 (46.7)</td>
</tr>
<tr>
<td>Left</td>
<td>32 (53.3)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>51-69</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>59.93 (8.71)</td>
</tr>
<tr>
<td><strong>Glaucoma diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Primary open angle</td>
<td>25 (41.7)</td>
</tr>
<tr>
<td>Pigmentary</td>
<td>2 (3.3)</td>
</tr>
<tr>
<td>Pseudoexfoliation glaucoma</td>
<td>5 (8.3)</td>
</tr>
<tr>
<td>Primary angle closure</td>
<td>28 (46.7)</td>
</tr>
<tr>
<td><strong>Time between trabeculectomy and phacoemulsification (months)</strong></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>12-18</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>12 (4.58)</td>
</tr>
<tr>
<td><strong>Number of glaucoma medications before phacoemulsification</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>30 (50.0)</td>
</tr>
<tr>
<td>1</td>
<td>26 (43.3)</td>
</tr>
<tr>
<td>2</td>
<td>4 (6.7)</td>
</tr>
<tr>
<td>3</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>
Table 2
Comparison of preoperative and postoperative intraocular pressure at each follow-up visit.

<table>
<thead>
<tr>
<th>Intraocular pressure (mmHg)</th>
<th>Follow-up</th>
<th>Mean (SD)</th>
<th>Range</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preoperative</td>
<td>12.42 (4.61)</td>
<td>4-21</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Month 1</td>
<td>14.98 (4.18)</td>
<td>10-30</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Month 3</td>
<td>14.47 (3.05)</td>
<td>10-28</td>
<td>0.015</td>
</tr>
<tr>
<td></td>
<td>Month 6</td>
<td>15.44 (3.60)</td>
<td>10-23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Month 12</td>
<td>15.71 (3.47)</td>
<td>9-23</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Table 3
Comparison of preoperative and postoperative glaucoma medication at each follow-up visit.

<table>
<thead>
<tr>
<th>Number of medications</th>
<th>Preoperative</th>
<th>Month 1</th>
<th>Month 3</th>
<th>Month 6</th>
<th>Month 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>30 (50.0)</td>
<td>26 (43.3)</td>
<td>26 (43.3)</td>
<td>26 (43.3)</td>
<td>26 (43.3)</td>
</tr>
<tr>
<td>1</td>
<td>26 (43.3)</td>
<td>29 (48.3)</td>
<td>27 (45.0)</td>
<td>27 (45.0)</td>
<td>23 (38.3)</td>
</tr>
<tr>
<td>2</td>
<td>4 (6.7)</td>
<td>5 (8.3)</td>
<td>6 (10.0)</td>
<td>5 (8.3)</td>
<td>4 (6.7)</td>
</tr>
<tr>
<td>3</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>4 (6.7)</td>
<td>2 (3.3)</td>
</tr>
<tr>
<td>Total</td>
<td>60 (100)</td>
<td>60 (100)</td>
<td>60 (100)</td>
<td>59* (98.3)</td>
<td>55† (91.7)</td>
</tr>
</tbody>
</table>

| Mean deviation        | 0.57         | 0.65     | 0.7     | 0.68     | 0.67     |
| Standard deviation    | 0.63         | 0.63     | 0.72    | 0.7      | 0.77     |

* One patient did not administer the medication as prescribed and was excluded from this analysis.
† Five patients did not administer the medication as prescribed and were excluded from this analysis.
<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Follow-up (months)</th>
<th>Success rate (%)</th>
<th>Definition of success</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seah and Jap\textsuperscript{15}</td>
<td>6</td>
<td>13.6</td>
<td>67</td>
<td>IOP 19 mmHg with no additional surgery or medications</td>
<td>Retrospective</td>
</tr>
<tr>
<td>Chen et al.\textsuperscript{6}</td>
<td>57</td>
<td>17.6</td>
<td>74</td>
<td>No additional medications, bleb needling, or glaucoma surgery</td>
<td>Retrospective</td>
</tr>
<tr>
<td>Park et al.\textsuperscript{5}</td>
<td>40</td>
<td>20.1</td>
<td>80 (3 years)</td>
<td>No increase in medications; IOP 21 mmHg or 20% reduction on 2 consecutive visits compared with pre-trabeculectomy</td>
<td>Case control</td>
</tr>
<tr>
<td>Manoj et al.\textsuperscript{9}</td>
<td>21</td>
<td>15.1</td>
<td>100</td>
<td>IOP 18 mmHg and within the target pressure</td>
<td>Retrospective</td>
</tr>
<tr>
<td>Crichton and Kirker\textsuperscript{14}</td>
<td>69</td>
<td>23.2</td>
<td>77</td>
<td>No additional surgery and no additional medications compared with pre-cataract surgery</td>
<td>Retrospective</td>
</tr>
<tr>
<td>Rebolleda and Muñoz-Negrete\textsuperscript{7}</td>
<td>49</td>
<td>19.5</td>
<td>67.4</td>
<td>No glaucoma medications, surgery, or bleb needling to control IOP</td>
<td>Prospective</td>
</tr>
<tr>
<td>Present study</td>
<td>60</td>
<td>12</td>
<td>71.67</td>
<td>IOP &lt;21 mmHg with 1 or 2 antiglaucoma medications and bleb needling to control IOP</td>
<td>Prospective</td>
</tr>
</tbody>
</table>